Oct 13, 2023 / 08:30PM GMT
Sarah Connors - Kronos Bio, Inc. - Vice President of Investor Relations & Corporate Communications
Thank you, operator, and good afternoon, everyone. I'm Sarah Connors, Vice President of Investor Relations and Corporate Communications at Kronos Bio. Earlier today, we issued a press release on Kronos Bio's positive preliminary data from the Phase 1 dose escalation portion of the Phase 1/2 KB-0742 study at AACR Triple Meeting. You may find this press release on our website, kronosbio.com in the Investors section.
Today, you will hear from Kronos Bio management, including Dr. Norbert Bischofberger, President and Chief Executive Officer; and Dr. Jorge DiMartino, Chief Medical Officer and Executive Vice President of Clinical Development. Norbert and Jorge will provide a brief overview of Kronos Bio, our science, and the KB-0742 program.
KB-0742 is Kronos Bio's internally discovered, highly selective, oral cyclin dependent kinase 9 inhibitor being developed to treat MYC-dependent solid tumors. We are very pleased to have trial investigator. Dr. Miguel Villalona, Medical Oncologist and
Kronos Bio Inc Phase 1/2 KB-0742 Data Update Call Transcript
Oct 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers